Literature DB >> 19776381

Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease.

N A Aziz1, C K Jurgens, G B Landwehrmeyer, W M C van Roon-Mom, G J B van Ommen, T Stijnen, R A C Roos.   

Abstract

OBJECTIVE: Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in the HD gene (HTT). We aimed to assess whether interaction between CAG repeat sizes in the mutant and normal allele could affect disease severity and progression.
METHODS: Using linear regression and mixed-effects models, the influence of mutant and normal CAG repeat sizes interaction was assessed on 1) age at onset in 921 patients with HD, 2) clinical severity and progression in 512 of these patients with follow-up data available, and 3) basal ganglia volume on magnetic resonance images in 16 premanifest HD mutation carriers.
RESULTS: Normal and mutant CAG repeat sizes interacted to influence 1) age at onset (p = 0.001), 2) severity or progression of motor, cognitive, and functional, but not behavioral, symptoms in patients with HD (all p < 0.05), and 3) in premanifest subjects, basal ganglia volumes (p < 0.05). In subjects with mutant CAG expansions in the low range, increasing size of the normal repeat correlated with more severe symptoms and pathology, whereas for those subjects with expansions in the high range, increasing size of the normal repeat correlated with less severe symptoms and pathology.
CONCLUSIONS: Increasing CAG repeat size in normal HTT diminishes the association between mutant CAG repeat size and disease severity and progression in Huntington disease. The underlying mechanism may involve interaction of the polyglutamine domains of normal and mutant huntingtin (fragments) and needs further elucidation. These findings may have predictive value and are essential for the design and interpretation of future therapeutic trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19776381     DOI: 10.1212/WNL.0b013e3181bd1121

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study.

Authors:  H Jacobi; P Bauer; P Giunti; R Labrum; M G Sweeney; P Charles; A Dürr; C Marelli; C Globas; C Linnemann; L Schöls; M Rakowicz; R Rola; E Zdzienicka; T Schmitz-Hübsch; R Fancellu; C Mariotti; C Tomasello; L Baliko; B Melegh; A Filla; C Rinaldi; B P van de Warrenburg; C C P Verstappen; S Szymanski; J Berciano; J Infante; D Timmann; S Boesch; S Hering; C Depondt; M Pandolfo; J-S Kang; S Ratzka; J Schulz; S Tezenas du Montcel; T Klockgether
Journal:  Neurology       Date:  2011-08-10       Impact factor: 9.910

2.  Longitudinal change in regional brain volumes in prodromal Huntington disease.

Authors:  Elizabeth H Aylward; Peggy C Nopoulos; Christopher A Ross; Douglas R Langbehn; Ronald K Pierson; James A Mills; Hans J Johnson; Vincent A Magnotta; Andrew R Juhl; Jane S Paulsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-09-30       Impact factor: 10.154

Review 3.  Differential diagnosis of chorea.

Authors:  Ruth H Walker
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

4.  Drosophila Models of Huntington's Disease exhibit sleep abnormalities.

Authors:  Erin Gonzales; Jerry Yin
Journal:  PLoS Curr       Date:  2010-09-29

5.  Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington's disease.

Authors:  Irene Ciancarelli; Daniela De Amicis; Caterina Di Massimo; Giorgio Sandrini; Caterina Pistarini; Antonio Carolei; Maria Giuliana Tozzi Ciancarelli
Journal:  Funct Neurol       Date:  2015 Jan-Mar

6.  C9orf72 expansion as a possible genetic cause of Huntington disease phenocopy syndrome.

Authors:  Vladimir S Kostić; Valerija Dobričić; Iva Stanković; Vesna Ralić; Elka Stefanova
Journal:  J Neurol       Date:  2014-07-18       Impact factor: 4.849

7.  Wild type huntingtin toxicity in yeast: Implications for the role of amyloid cross-seeding in polyQ diseases.

Authors:  A I Alexandrov; G V Serpionov; V V Kushnirov; M D Ter-Avanesyan
Journal:  Prion       Date:  2016-05-03       Impact factor: 3.931

8.  Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes.

Authors:  Sophie Tezenas du Montcel; Alexandra Durr; Peter Bauer; Karla P Figueroa; Yaeko Ichikawa; Alessandro Brussino; Sylvie Forlani; Maria Rakowicz; Ludger Schöls; Caterina Mariotti; Bart P C van de Warrenburg; Laura Orsi; Paola Giunti; Alessandro Filla; Sandra Szymanski; Thomas Klockgether; José Berciano; Massimo Pandolfo; Sylvia Boesch; Bela Melegh; Dagmar Timmann; Paola Mandich; Agnès Camuzat; Jun Goto; Tetsuo Ashizawa; Cécile Cazeneuve; Shoji Tsuji; Stefan-M Pulst; Alfredo Brusco; Olaf Riess; Alexis Brice; Giovanni Stevanin
Journal:  Brain       Date:  2014-06-26       Impact factor: 13.501

9.  Cytotoxicity of mutant huntingtin fragment in yeast can be modulated by the expression level of wild type huntingtin fragment.

Authors:  Aliabbas Ahmedbhai Saleh; Ankan Kumar Bhadra; Ipsita Roy
Journal:  ACS Chem Neurosci       Date:  2014-01-08       Impact factor: 4.418

10.  Huntington's Disease-Induced Cardiac Disorders Affect Multiple Cellular Pathways.

Authors:  Girish C Melkani
Journal:  React Oxyg Species (Apex)       Date:  2016-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.